

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

HT

RRID:CVCL_1290

Type: Cell Line

Proper Citation

RRID:CVCL_1290

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1290

Proper Citation: RRID:CVCL_1290

Description: Cell line HT is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: [PMID:2313723](#), [PMID:19278952](#), [PMID:19358282](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20628145](#), [PMID:22460905](#), [PMID:23257783](#), [PMID:23292937](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:26787899](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29416618](#), [PMID:29666304](#), [PMID:30165192](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HT

Cross References: CLO:CLO_0004265, EFO:EFO_0002200, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:CRL-2260, BCRC:60486, BioSample:SAMN01821562, BioSample:SAMN01821633, BioSample:SAMN03472827, BioSample:SAMN03473482, BioSample:SAMN10987949, cancercellines:CVCL_1290, Cell_Model_Passport:SIDM00661, ChEMBL-Cells:ChEMBL3308143, ChEMBL-

Targets:CHEMBL2366130, Cosmic:687844, Cosmic:907063, Cosmic:1067441, Cosmic:1541915, Cosmic:1945181, Cosmic:2022501, Cosmic:2276317, Cosmic-CLP:907063, DepMap:ACH-000914, DSMZ:ACC-567, DSMZCellDive:ACC-567, EGA:EGAS00001000610, EGA:EGAS00001002554, GDSC:907063, GEO:GSM274841, GEO:GSM380127, GEO:GSM552431, GEO:GSM562824, GEO:GSM887143, GEO:GSM888215, GEO:GSM1035314, GEO:GSM1059806, GEO:GSM1151288, GEO:GSM1374558, GEO:GSM1669907, IARC_TP53:21377, IGRhCellID:HT, Kerafast:EMI025, LiGeA:CCL_740, LINCS_LDP:LCL-1949, PharmacDB:HT_624_2019, PRIDE:PXD030304, Progenetix:CVCL_1290, PubChem_Cell_line:CVCL_1290, Wikidata:Q54896490

ID: CVCL_1290

Record Creation Time: 20220427T220617+0000

Record Last Update: 20260829T234242+0000

Ratings and Alerts

No rating or validation information has been found for HT.

No alerts have been found for HT.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

McCrury M, et al. (2024) Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Molecular cancer therapeutics, 23(3), 316.

Gleason CE, et al. (2024) Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(4), 703.

Zhang J, et al. (2020) Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation. *Cell chemical biology*, 27(12), 1500.